Wolverine Trading’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-7,811
Closed -$678K 4784
2024
Q4
$678K Buy
7,811
+1,947
+33% +$178K ﹤0.01% 3059
2024
Q3
$543K Sell
5,864
-3,664
-38% -$364K ﹤0.01% 2977
2024
Q2
$1.03M Buy
+9,528
New +$954K ﹤0.01% 2170
2023
Q4
Sell
-6,888
Closed -$346K 4508
2023
Q3
$346K Buy
+6,888
New +$368K ﹤0.01% 3152
2023
Q2
Sell
-4,545
Closed -$201K 4275
2023
Q1
$201K Buy
+4,545
New +$205K ﹤0.01% 3406

Other funds holding BPMC

Wolverine Trading's BPMC Position: Q1 2025 in Review

Wolverine Trading sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 7,811 shares — an estimated $678K sold.

Wolverine Trading first reported a position in BPMC in Q1 2023 and held it in 5 quarters. The position peaked at $1.03M in Q2 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Wolverine Trading reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Wolverine Trading sold 7,811 Blueprint Medicines shares in Q1 2025, an estimated $678K.
  • Wolverine Trading first reported a position in Blueprint Medicines in Q1 2023 and held it in 5 quarters.
  • Wolverine Trading's Blueprint Medicines position peaked at $1.03M in Q2 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Wolverine Trading's 13F filing for Q1 2025, filed 15 May 2025.